GUANGZHOU, China — China's medical device and pharmaceutical exporters are turning their attention to Central and Eastern Europe (CEE), as a new national cross-border trading platform launched in Ningbo in September signals stronger government support for overseas expansion.
New Platform Opens
On September 22, the Ningbo-CEE Pharmaceutical Trading (Procurement) Platform officially went live. Guided by the National Healthcare Security Administration, it is the first specialized cross-border pharmaceutical trading platform targeting CEE markets and one of four designated international export hubs.
The platform currently hosts nearly 500 Chinese suppliers, over 20 overseas buyers, and lists more than 4,000 products across six categories: active pharmaceutical ingredients, formulations, traditional Chinese medicine pieces, medical consumables, diagnostic reagents and medical devices. In its first six months of trial operation, transaction volume exceeded RMB 200 million, with products already entering Italy, Serbia and other markets.
Trade Growth Continues
According to Chinese customs data, total pharmaceutical trade between China and CEE reached USD 5.22 billion in 2025, up 9.8% year on year. Exports rose 10% to USD 3.32 billion. In the first half of 2026, bilateral trade reached USD 2.71 billion, up 8.1%.
Challenges Remain
Despite the growth opportunity, the article identifies four key barriers for Chinese companies entering CEE:
- Fragmented regulation — EU central approval (EMA) plus national pricing and HTA reviews; innovative drugs take an average of 705 days for reimbursement.
- Intense competition — Western originator drugs dominate, while Indian generics gain price advantage.
- Pricing pressure — external reference pricing (ERP), clawback and mandatory rebates compress net prices.
- Localization requirements — distribution is concentrated among a few large chains, and EU GMP manufacturing presence is increasingly required.
Recommended Strategy
The report suggests companies:
- Tier markets (Czech Republic, Slovenia, Poland as priority; Hungary as a manufacturing hub);
- Model net prices accounting for rebates and ERP;
- Prepare HTA-compliant evidence packages;
- Differentiate between innovative drugs (EMA pathway) and generics (tender participation);
- Partner locally rather than entering directly.
For SaferLife Products Co., Ltd., CEE represents a growing opportunity for medical devices such as pulse oximeters, examination beds and emergency products, alongside our existing cooperation with distributors worldwide.